476620-54-9

Basic information

• Product Name: 2-Bromo-4,5-difluorobenzaldehyde
• Synonyms: 2-Bromo-4,5-difluorobenzaldehyde
• CAS NO: 476620-54-9
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 220.9989264
• Mol File: 476620-54-9.mol

Chemical Properties

• Boiling Point: 232.0±35.0 °C(Predicted)
• Appearance: Off-white/Powder
• Density: 1.758±0.06 g/cm3(Predicted)
• Storage Temp.: Room temperature.
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-Bromo-4,5-difluorobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4,5-difluorobenzaldehyde(476620-54-9)
• EPA Substance Registry System: 2-Bromo-4,5-difluorobenzaldehyde(476620-54-9)

Safety Data

• Hazardous Substances Data: 476620-54-9(Hazardous Substances Data)

Usage

Uses

It is an important intermediate for pharmaceutical and organic synthesis.

Upstream product

• 64695-78-9 1,2-difluoro-4,5-dibromobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 64695-84-7 2-bromo-4,5-difluorobenzoic acid 
• 476620-55-0 (2-bromo-4,5-difluorophenyl)methanol 

Downstream Products

• 1266728-05-5 2-(2-bromo-4,5-difluorophenyl)-1,3-dioxane 
• 959687-70-8 1-bromo-4,5-difluoro-2-(dimethoxymethyl)benzene 
• 1422359-20-3 C₁₄H₇BrF₅NO₂S 
• 1429329-42-9 C₁₈H₁₁BrF₅NO₃S 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

PRMT5 INHIBITORS

The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The inve

Synthesis and Transformations of Functionalized Benzosiloxaboroles

The synthesis and characterization of a series of fluorinated benzosiloxaboroles bearing synthetically useful formyl and cyano groups is reported. These compounds have been obtained by multistep syntheses starting with simple halogenated benzenes. The general synthetic protocol was based on the generation of ortho-boronated aryldimethylsilanes which undergo dehydrogenative cyclization upon hydrolytic workup due to activation of the Si–H bond by the adjacent boronic group. In some cases the synergy of adjacent boron- and silicon-based functionalities resulted in an unexpected hydrosilylation of the CHO group under mild aqueous conditions. The reduction of a benzosiloxaborole derivative bearing the formyl group at the ortho position with respect to the boron atom resulted in a structural transformation reflecting the higher stability of the carboxaborole heterocycle with respect to its silicon counterpart. Thus, a unique heterocyclic system featuring a central 10-membered ring comprising two borasiloxane linkages was isolated.

3,4-Diarylpiperidines as potent renin inhibitors

The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC50, had a clean CYP 3A4 profile and displayed mic

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS

Renin inhibitors which are spirocyclic piperidine derivatives, of formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency. or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of the stereoisomer thereof, wherein: n, for each instance in which it occurs, is independently 0, 1, or 2; W is a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring, A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a first five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to a second five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is -(C=O)-, -CH2- or =CH-; U is a bond or -CH2-, or, when V iS =CH-, U is-CH=; X is =CH-, =CF-, =C(OR3)-, or -(C=O)-; and Y is =CH-, =CF-, =N-, or, for the case when X is -(C=O)-, Y is -N(R3)-.

NAPHTHYLACETIC ACIDS

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.